RESULTS WITH HYRNUO

WHEN USING HYRNUO® AS FIRST TREATMENT

As part of a larger study, HYRNUO was studied in 69 people with NSCLC that had spread to their chest or to other parts of
their body.

3 out of 4 people icon with three dark blue figures and one outlined figure

75% OF PEOPLE HAD A CONFIRMED RESPONSE TO HYRNUO

In the clinical study, 6% of people (n=4) experienced a complete response, meaning the disappearance of
cancer cells.

Additionally, 70% of people (n=48) had a partial
response, meaning a decrease in the size of cancer of 30% or more.

blue-calendar

THE 52 PEOPLE WHO RESPONDED TO
HYRNUO HAD THEIR RESPONSE TO
TREATMENT LAST BETWEEN 1.5 MONTHS TO
21.6 MONTHS AND BEYOND

A majority of people (73%) saw their response to
treatment last at least 6 months, based on the data in
the study.

IN PEOPLE WHO WERE PREVIOUSLY TREATED BUT NEW TO HER2-TARGETED TREATMENT:

As part of a larger study, HYRNUO was studied in 70 people with NSCLC that had spread within their chest or to other
parts of their body.

7 out of 10 people icon with 7 in pink and 3 in white

71% OF PEOPLE HAD A CONFIRMED
RESPONSE TO HYRNUO

In the clinical study, 3% of people (n=2) experienced a complete response, meaning the disappearance of
cancer cells.

Additionally, 69% of people (n=48) had a partial
response, meaning a decrease in the size of cancer of
30% or more.

Calendar icon showing 9.2 months

25 OUT OF 50 PEOPLE WHO RESPONDED TO HYRNUO HAD A RESPONSE THAT LASTED 9.2 MONTHS

There was a range of time that people continued to see
results, with the highest likelihood that a response to
treatment (95%) would last between 6.3 to 15 months.

More than half of people (54%) saw their response to treatment last at least 6 months, based on the data in
the study.

IN PEOPLE WHO WERE PREVIOUSLY TREATED WITH TREATMENT THAT TARGETS HER2:

As part of a larger study, HYRNUO was studied in 52 people with NSCLC that had spread within their chest or to other
parts of their body.

Icon of 10 people with 4 out of the 10 pink and 6 in white

38% OF PEOPLE HAD A CONFIRMED
RESPONSE TO TREATMENT WITH HYRNUO

In a clinical study, 6% (n=3) experienced a complete
response, meaning the disappearance of cancer cells.

Additionally, 33% of people (n=17) had a partial
response, meaning a decrease in the size of cancer of
30% or more.

Calendar icon showing 7 months

10 OUT OF 20 PEOPLE WHO RESPONDED TO
HYRNUO HAD A RESPONSE THAT LASTED 7
MONTHS

There was a range of time that people continued to see
results, with the highest likelihood that a response to
treatment (95%) would last at least 5.6 months.

More than half of people (60%) saw their response to
treatment last at least 6 months, based on the data in
the study.

HYRNUO MAY CAUSE SIDE EFFECTS

The most common side effects of HYRNUO include:

  • diarrhea
  • rash
  • nail problems, including infection and inflammation
  • mouth sores
  • nausea
  • vomiting
  • changes in certain blood tests

Serious side effects of HYRNUO include:

    Diarrhea can be severe. This can cause your body to lose too much body
    fluid (dehydration) and salts (electrolyte imbalances). Diarrhea usually occurs
    around Day 4. At the first sign of diarrhea: 

    • Contact your healthcare provider immediately  
    • Drink plenty of fluids  
    • Start antidiarrheal treatment as soon as possible; you should have an

      antidiarrheal medicine available before you start taking HYRNUO

    Additional tips to consider when starting treatment:

    • Eat foods that are low in fiber
    • Try to eat several small meals per day instead of 2 or 3 larger ones
    • Avoid spicy food, dairy products, caffeine, and alcohol

      HYRNUO may cause severe liver problems, including increases in liver blood tests. Your healthcare provider will do blood tests to check your liver function before you start taking HYRNUO and during your treatment. Tell your healthcare provider right away if you notice signs or symptoms of liver problems, including yellowing of the skin or whites of the eyes, dark urine, pale stools, nausea or vomiting, loss of appetite, pain on the upper right side of your stomach, or tiredness or weakness.

        HYRNUO may cause severe lung problems. Tell your healthcare provider right away if you develop any new or worsening symptoms of lung problems, including cough, fever, shortness of breath, or trouble breathing.

          HYRNUO may cause severe heart problems that may affect your heart’s ability to pump blood. Your healthcare provider will do tests to check your heart function before you start taking HYRNUO and during your treatment. Tell your healthcare provider right away if you develop any new or worsening signs or symptoms of heart problems, including: shortness of breath, tiredness, coughing, irregular heartbeat, swelling of your legs, ankles, or feet, feeling dizzy or lightheaded, or loss of consciousness.

            HYRNUO can cause eye problems that can lead to temporary loss of vision. Tell your healthcare provider right away if you develop new or worsening signs or symptoms of eye problems. Your healthcare provider may send you to see an eye specialist (ophthalmologist).

              HYRNUO may cause increases in certain pancreatic blood tests (amylase and lipase). Your healthcare provider will do blood tests to check your pancreatic function during your treatment with HYRNUO. Tell your healthcare provider right away if you develop any signs or symptoms of pancreas problems, including upper stomach pain that may spread to your back and get worse with eating, weight loss, nausea, or vomiting. 

              These are not all the possible side effects of HYRNUO.

              Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

              HER2=human epidermal growth factor receptor 2; NSCLC=non-small cell lung cancer.

              PATIENTS NEWLY PRESCRIBED HYRNUO CAN RECEIVE 1 MONTH OF FREE THERAPY!